Arbutus and Barinthus (formerly Vaccitech plc) have entered into a clinical collaboration agreement to complete a clinical trial to evaluate treatment of AB-729, in combination with Vaccitech’s proprietary immunotherapeutic, VTP-300, in nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic HBV.

Tags